PIPs

He could have gone to (coincidentally) the excellent blog that Harvard Law School has on corporate governance for some cliffnotes on the climate change interpretive release put out in early 2010 that contained a lot of good guidance for corporate attorneys about disclosure of risk factors. This release did not say anything that was not already law, but it was meant to give corporate lawyers a "heads up" that risk factors were going to be a major focus of regulators and law enforcement.

If he ever did, he would have seen the Harvard Law's blog interpretation of these issues and would have seen this:

"Notwithstanding its focus on disclosure of one category of risks – climate change – this release has much broader significance for companies regarding the duty to provide “early warning” to investors of all types of contingencies that, if realized, could have a material effect (whether negative or positive) on a company’s financial condition and results of operations. The primary objective of this analysis is to shed light for investors on factors that are “reasonably likely to cause reported financial information not to be necessarily indicative of future operating performance or future financial condition.”

 

No I disagree. Community urology sales were up 25% in Q4 for provenge. This was a direct offset to the 16% decline in Q4 Zytiga sales.

 

I agree - the planet is undergoing "climate change". What does this have to do with Dendreon? OCD

 

Lol, PR dept hard at work. Almost as strange as the time when a paid spokesperson, not an employee included themselves in a legal opinion by saying "we believe" instead of "the company believes" about a derivative suit that is seeking to recover damages from individuals and have the company be the beneficiary. One would think this would be great for cancer patients and the company would welcome something like that!!

 

"Notwithstanding its focus on disclosure of one category of risks – climate change – this release has much broader significance for companies regarding the duty to provide “early warning” to investors of all types of contingencies."

The interpretive release from February 2010 focused on one category of risk factors (climate change risk factors for companies that have risk factors relating to climate change), BUT the release has BROAD significance for ALL public companies regarding the disclosure of risk factors.

 

“While it is our practice not to comment on litigation, we believe this suit is baseless and without merit,” Lindsay Rocco, a spokeswoman for Dendreon, said in an e-mailed message.

It was Lindsay.

Apparently her extra zeal in mentioning the company practice not to comment and commenting anyway and including herself in the opinion impressed management.

She was later hired as an executive and recently was awarded 50,000 shares.

 

Hopefully you will be hearing from Lindsay and Christine soon.

 

Who is Christine?

 

Now get ready for three way ride along, rsd, dm and then the only one who works, the rep! No trust at all from management here. Tom please control your directors

 

It is truly something that would have given anyone with half a brain and a little common sense serious pause. Could have been written in 2 sentences. Makes you wonder why it was left out.

 

god forbid if it was premeditated.

 

Goodie! I guess the NSM didn't provide confidence to the directors in our clinical conviction and that is why 1st Qtr is off to a blast...soft...soft... oh yeah I know "D is a great place to work", "I got alot out of the meeting", "the sales management knows what its doing and we are poised for a turn around"!
Drive it up your ass at your Runzheimer rate.

 

Maybe you should get a job at Dendreon before you comment on the NSM or Q1. The
NSM went well and Q1 is going well.

 

Ha-good luck with that senior mgmt! They will be sitting in a lot of waiting rooms as most account will only allow 1 MAYBE 2 people into accounts at a time. Their old primary care tactics no longer work. Oh but wait- most newbies have never sold in oncology. My bad.

 

The newbies can go into chief compliance officer training! No experience needed!

 

Poster 114 is absolutely right. I came to this company after being gone from pharma for a long time. When I left pharma this model had crashed. Imagine my surprise when I joined Dendreon, went to my first NSM and watched leadership talking about "deliver these key messages on every call" and "we have new fantastic marketing pieces with new messages"


Folks, no one in the real world takes time to look at marketing piece or listen to anyone holding a marketing piece.

This old play from early 2000 is not going to yield the results this company needs.

 

Failed sales strategies are one thing. Denial and harboring is unacceptable. To think you are outsmarting when everything is so out in the open is pure stupidity. Advice like that is so poor it almost seems like malpractice.

 

Deceptively dumb. Everything is transparent. Even some PR's I've seen.